PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues.

Cancer Drug Resist · 2019 · PMC8992523 · PMID 35582575

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

OlympiAD was not powered to detect a difference in overall survival, although there was a nonsignificant trend towards improvement in the olaparib arm.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.